Citations 2
Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma
Jones, Robin L. , Ravi, Vinod , Brohl, Andrew S. , Chawla, Sant P. , Ganjoo, Kristen N. , Italiano, Antoîne , Attia, Steven , Thornton, Katherine A., Cranmer, Lee D. , Cheang, Maggie C.U. , Liu, Lingyun , Robertson, Liz, Adams, Bonne J., Theuer, Charles P. , Maki, Robert G. , Maki, Robert G , Jones, Robin L , Cheang, Maggie Chon U , Italiano, Antoine , Burgess, Melissa
JAMA Oncology | March 31, 2022 | Volume: 8 | Issue: 5 | Pages: 740
TAPPAS: An adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma.
Ravi, Vinod , Chawla, Sant P. , Attia, Steven , Riedel, Richard F. , Thornton, Katherine A., Mallick, Atrayee Basu , Liu, Lingyun , Alvarez, Delia, Theuer, Charles P. , Tap, William D. , Jones, Robin L. , Maki, Robert G. , Maki, Robert G , Riedel, Richard F , Jones, Robin L , Brohl, Andrew S. , Liebner, David A. , Mehta, Cyrus R. , Robinson, Steven I. , Penel, Nicolas , Stacchiotti, Silvia
Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: TPS11590-TPS11590